C11orf75_BC017612 Inhibitors
C11orf75_BC017612 inhibitors encompass a range of compounds that act on various signaling pathways that this protein is known to be involved in or pathways that its activity could potentially depend upon. These compounds inhibit specific kinases or signaling nodes that, when disrupted, could lead to the reduced activity of C11orf75_BC017612. For example, Src family kinases play a pivotal role in various cellular signaling pathways, and their activity can be inhibited by compounds such as PP2 and Dasatinib. If C11orf75_BC017612 requires Src kinase signaling for its function, inhibition by these compounds would result in its decreased activity. Similarly, the PI3K/AKT and MEK/ERK pathways are critical for a wide range of cellular functions, including cell growth and survival. Compounds like LY294002 and U0126, which target PI3K and MEK respectively, would lead to decreased C11orf75_BC017612 activity if it is functionally dependent on these signaling cascades.
In addition to these pathways, the mTOR signaling pathway is another crucial regulator of cell growth and metabolism. Compounds like Rapamycin,PP242, and AZD8055 are potent mTOR inhibitors, which, by inhibiting mTORC1 and mTORC2, could reduce C11orf75_BC017612 activity if it is regulated by mTOR signaling. Other compounds such as PF-562271 function as focal adhesion kinase (FAK) inhibitors, which could lead to decreased C11orf75_BC017612 activity by disrupting FAK-mediated signaling pathways. Moreover, JNK and p38 MAPK pathways are involved in stress responses and apoptosis, with SP600125 and SB203580 serving as their respective inhibitors. The inhibition of these MAPK pathways would potentially decrease the activity of C11orf75_BC017612 if its functional role is connected to these signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Src family kinase inhibitor that impedes Src kinase activity. C11orf75_BC017612 is implicated in signaling pathways that are dependent on Src kinase-mediated phosphorylation events. Inhibition of Src by PP2 would lead to a reduction in C11orf75_BC017612 activity if it requires Src kinase signaling for its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A multi-targeted tyrosine kinase inhibitor that strongly inhibits Src family kinases. By inhibiting Src kinases, Dasatinib would decrease the phosphorylation of substrates involved in the signaling pathways that C11orf75_BC017612 is a part of, leading to its decreased activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor with activity against ABL kinase. Since ABL kinase can interact with various signaling pathways, inhibition by Imatinib can lead to reduced C11orf75_BC017612 activity if ABL kinase signaling is necessary for C11orf75_BC017612 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that prevents the activation of AKT. C11orf75_BC017612, being involved in PI3K/AKT signaling, would have decreased activity upon inhibition of this pathway by LY294002. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, which in turn prevents ERK1/2 activation. If C11orf75_BC017612 operates within the MEK/ERK pathway, its activity would be diminished by the action of U0126. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
An inhibitor of p38 MAPK which could decrease C11orf75_BC017612 activity by inhibiting p38 MAPK-mediated signaling pathways if C11orf75_BC017612 is regulated by these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An ATP-competitive inhibitor of JNK1/2/3 which would lead to decreased C11orf75_BC017612 activity if C11orf75_BC017612 is involved in JNK signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that binds to FKBP12 and inhibits mTORC1. If C11orf75_BC017612 activity is linked to mTOR signaling, Rapamycin would decrease its activity by inhibiting this pathway. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
A selective mTOR inhibitor that targets both mTORC1 and mTORC2, potentially decreasing C11orf75_BC017612 activity if C11orf75_BC017612 is regulated by mTOR signaling. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
A focal adhesion kinase (FAK) inhibitor that would reduce C11orf75_BC017612 activity by inhibiting FAK if C11orf75_BC017612 is involved in FAK-mediated signaling pathways. | ||||||